Search Results
Dec 14, 2025, 22:00 ET Moutai Returns to its Origin of World Fame, 110 Years from its Debut on Panama Expo
III. Toasting at "Moutai Night": Crafting Shared Value Through AromaOn the evening of December 7, Kweichow Moutai hosted a Moutai Night to commemorate
More news about: Kweichow Moutai
Dec 14, 2025, 10:20 ET FCX INVESTOR NOTICE: Freeport McMoRan Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
(ii) the lack of proper safety precautions constituted a heightened risk that could foreseeably lead to the death of Freeport-McMoRan's workers; and (iii) this constituted an undisclosed heightened risk of regulatory, litigation, and reputational risk.The Freeport-McMoRan class action lawsuit
More news about: Robbins Geller Rudman & Dowd LLP
Dec 12, 2025, 22:06 ET Jayud Global Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Jayud Global Logistics Limited - JYD
(ii) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (iii) the Company's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity elevating the stock price;
More news about: ClaimsFiler
Dec 12, 2025, 22:03 ET Six Flags Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Six Flags Entertainment Corporation - FUN
cost-cutting measures, including significant reductions in employee headcount, which materially degraded operational competence and guest experience; (iii) as a result, Legacy Six Flags required a substantial and undisclosed capital infusion to stabilize and revitalize its business, and these acute capital
More news about: ClaimsFiler
Dec 12, 2025, 20:53 ET Shrub Oak International School Appoints Nancy Tritsch, MS Ed, EdM, as Director of Education
support.Shrub Oak International School is accredited by:The National Independent Private Schools Association (NIPSA), Level III Therapeutic Certification, Academic Accreditation, with an Autism Endorsement;The Middle States Association Commission on Elementary and Secondary
More news about: Shrub Oak International School
Dec 12, 2025, 20:18 ET REVERE TACTICAL OPPORTUNITIES REIT, LLC AND REVERE TACTICAL OPPORTUNITIES FUND IV, LP TO AUCTION 100% OF THE CLASS B LIMITED PARTNER INTEREST IN CASORO AVIATOR INVESTORS, LP VIA PUBLIC SALE
or other evidence acceptable to Secured Party that will show the financial ability of the Potential Bidder to purchase the Public Sale Collateral, (iii) a completed and executed Asset Purchase Agreement in the form provided by Secured Party, and (iv) a deposit in an amount equal to ten percent of the
More news about: Revere Capital
Dec 12, 2025, 18:57 ET Ferrovial announces the termination of its existing share repurchase program and the implementation of a new share repurchase program
million Ferrovial shares, representing approximately 2.04% of Ferrovial's issued share capital as of the date of this announcement.(iii) Price and volume conditions: The shares will be acquired in accordance with the relevant authorization of the Company's general meeting.
More news about: Ferrovial
Dec 12, 2025, 16:29 ET Oklahoma Proton Center lauds results of groundbreaking clinical study
The Lancet, showed results from the largest of its kind Phase III trial. Led by researchers at the University of Texas MD Anderson Cancer Center, this multi-institutional comparative study enrolled hundreds of patients
More news about: Oklahoma Proton Center
Dec 12, 2025, 11:17 ET DEFT DEADLINE: Faruqi & Faruqi Reminds DeFi Technologies Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 30, 2026 - DEFT
other DAT companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly,
More news about: Faruqi & Faruqi, LLP
Dec 12, 2025, 09:18 ET AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy
(2024 - 2025), and APASL (2025). AHB-137 has completed a global Phase I study and is currently being evaluated in multiple Phase II studies and a phase III trial in China. Supported by a coordinated global development strategy, AHB-137 is advancing toward its goal of delivering a potential functional cure
More news about: AusperBio Therapeutics Inc.
Dec 12, 2025, 09:00 ET Levi & Korsinsky Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SKYE
effective than defendants had led investors to believe; (ii) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.WHAT'S NEXT? If you suffered a loss
More news about: Levi & Korsinsky, LLP
Dec 12, 2025, 09:00 ET Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of DeFi Technologies(DEFT) Shareholders
treasury companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly,
More news about: Levi & Korsinsky, LLP
Dec 12, 2025, 09:00 ET Class Action Filed Against DexCom, Inc. (DXCM) - December 26, 2025 Deadline to Join - Contact Levi & Korsinsky
and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants
More news about: Levi & Korsinsky, LLP
Dec 12, 2025, 09:00 ET Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Firefly Aerospace Inc.(FLY) Shareholders
for its Spacecraft Solutions offerings; (ii) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program; (iii) the foregoing, once revealed, would likely have a material negative impact on the Company; and (iv) as a result, the offering documents and defendants'
More news about: Levi & Korsinsky, LLP
Dec 12, 2025, 07:00 ET Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
antibiotic, Taigexyn® (Nemonoxacin), is approved in Taiwan, China, and Russia, while the influenza antiviral TG-1000 has completed Phase III trials and filed an NDA in China.
More news about: Insilico Medicine
Dec 12, 2025, 00:38 ET TELUS Announces Upsizing and Results of its Cash Tender Offers for Seven Series of Debt Securities
to, or for the account or benefit of, any "U.S. person" (as such term is defined in Regulation S of the U.S. Securities Act of 1933, as amended); or (iii) to participate in the Offers in any jurisdiction in which it is unlawful to make such an offer or solicitation in such jurisdiction, and such persons
More news about: TELUS Corporation
Dec 12, 2025, 00:38 ET TELUS Announces Upsizing and Results of its Cash Tender Offers for Seven Series of Debt Securities
to, or for the account or benefit of, any "U.S. person" (as such term is defined in Regulation S of the U.S. Securities Act of 1933, as amended); or (iii) to participate in the Offers in any jurisdiction in which it is unlawful to make such an offer or solicitation in such jurisdiction, and such persons
More news about: TELUS Corporation
Dec 11, 2025, 23:40 ET BEKANNTMACHUNG ÜBER DIE GENEHMIGUNG EINES VERGLEICHS ITHACA ENERGY INC. jetzt bekannt als ITHACA ENERGY LIMITED SECURITIES CLASS ACTION SECURITIES CLASS ACTION
anderem folgende Aufgaben hat (i) Anspruchsformulare entgegenzunehmen und zu bearbeiten; (ii) über die Berechtigung zur Entschädigung zu entscheiden; und (iii) den Netto-Vergleichsbetrag an berechtigte Sammelkläger zu verteilen. Das Antragsformular ist über das gesicherte Online-Antragssystem unter
More news about: Berger Montague
Dec 11, 2025, 21:31 ET Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study will compare cadonilimab plus chemotherapy
More news about: Akeso, Inc.
Dec 11, 2025, 19:00 ET Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage.Innovent partners with over 30 global healthcare companies, including
More news about: Innovent Biologics
Dec 11, 2025, 18:56 ET ITGR INVESTOR ALERT: Integer Holdings Corporation Investors with Substantial Losses Have Opportunity to Lead the Integer Holdings Class Action Lawsuit
strong visibility into customer demand, Integer Holdings was experiencing a sustained deterioration in sales relating to two of its EP devices; and (iii) in turn, Integer Holdings mischaracterized its EP devices as a long-term growth driver for its Cardio & Vascular segment.The Integer Holdings
More news about: Robbins Geller Rudman & Dowd LLP
Dec 11, 2025, 18:31 ET New Lancet Phase III Study Shows Proton Therapy Significantly Improves Survival and Reduces Toxicity in Head and Neck Cancers - Marking a Breakthrough in Advanced Cancer Care
The Lancet showed results from the largest of its kind Phase III trial demonstrating a significant survival benefit for patients with oropharyngeal cancers who were treated with proton therapy compared to traditional
More news about: The National Association for Proton Therapy
Dec 11, 2025, 18:09 ET FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
MuSK+.6Eligibility criteria at screening and randomization included a Myasthenia Gravis Foundation of America (MGFA) classification of II, III or IV disease, MG-ADL score between 6 and 10 with greater than 50% of this score attributed to non-ocular items, or an MG-ADL score of at least 11, and
More news about: Amgen
Dec 11, 2025, 17:58 ET NOTICE OF SETTLEMENT APPROVAL ITHACA ENERGY INC. now known as ITHACA ENERGY LIMITED SECURITIES CLASS ACTION SECURITIES CLASS ACTION
PC as the Administrator of the settlement to, among other things: (i) receive and process Claim Forms; (ii) decide eligibility for compensation; and (iii) distribute the net Settlement Amount to eligible Class Members. The Claim Form should be submitted to the Administrator by using the secure Online Claims
More news about: Berger Montague
Dec 11, 2025, 17:31 ET Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
CareJohnson & Johnson unveiled late-breaking results from the Phase III MajesTEC-3 study, presenting what has been characterized as the most impressive progression-free survival (PFS) benefit ever demonstrated in a Phase III multiple myeloma trial. The study evaluated the combination of TECVAYLI
More news about: DelveInsight Business Research, LLP